Mainly in virtue of these characteristics, CD38 has been adopted by pharmaceutical companies as an ideal target for antibody-mediated in vivo therapy of MM, a diagnosis that is becoming increasingly common worldwide. Here, CD38 is linked to Miyoshi myopathy.